RALY Antibody

What is RALY protein and why do researchers study it?

RALY (RNA-binding protein Raly) functions as a nuclear ribonucleoprotein primarily localized in the nucleus with partial distribution in the cytoplasm. It contains an RNA recognition motif (RRM) that facilitates interaction with RNA molecules . Recent research has identified RALY as a critical inhibitor of viral replication, specifically for foot-and-mouth disease virus (FMDV), where it binds to domain 3 of the FMDV IRES and blocks 80S ribosome assembly, thus inhibiting IRES-driven translation . This antiviral activity makes RALY an important target for understanding host-pathogen interactions and potential therapeutic development.

What types of RALY antibodies are available for research?

Currently, rabbit polyclonal antibodies against RALY are most commonly used in research settings. These include antibodies generated against recombinant fusion proteins containing amino acid sequences corresponding to human RALY (NP_057951.1) . Commercially available options include the HPA043614 antibody from Atlas Antibodies and the A81095 antibody with documented reactivity against human, mouse, and rat RALY . These polyclonal antibodies are typically affinity-purified and supplied in buffers containing phosphate-buffered saline with glycerol and preservatives .

What applications are RALY antibodies validated for?

RALY antibodies have been validated for multiple research applications including:

• Western blotting (WB) with recommended dilutions of 1:500-1:1,000

• Immunohistochemistry (IHC) in tissues such as testis and liver

• RNA immunoprecipitation (RIP) for studying RNA-protein interactions

• Immunoprecipitation (IP) assays to investigate protein-protein interactions

• Sucrose gradient fractionation studies to analyze ribosomal association

Each application requires specific optimization protocols to ensure reliable results in detecting the approximately 38 kDa RALY protein .

How should RNA immunoprecipitation with RALY antibodies be performed?

For effective RNA immunoprecipitation using RALY antibodies:

• Infect target cells (e.g., BHK-21) with virus of interest at appropriate MOI (e.g., MOI=1)

• At specified timepoint post-infection (e.g., 5 hpi), harvest and lyse cells with RIPA buffer containing protease and RNase inhibitors

• Pre-clear lysate with protein G beads for 1 hour on ice

• Add 8 μL of anti-RALY antibody (include IgG and no-antibody controls)

• Incubate overnight at 4°C with rotation

• Add pre-treated protein G beads and incubate 2-4 hours at 4°C

• Collect immune complexes by centrifugation (3,000 × g, 5 min, 4°C)

• Wash three times with lysis buffer

• Extract RNA with TRIzol reagent

• Perform RT-PCR analysis using appropriate primers

This protocol has successfully demonstrated RALY's interaction with FMDV IRES elements, establishing its role in antiviral activity .

What is the optimal protocol for Western blotting with RALY antibodies?

For optimal Western blotting results with RALY antibodies:

• Separate proteins via SDS-PAGE

• Transfer to PVDF membranes

• Block with 1× TBST containing 5% skimmed milk for 1 hour

• Incubate with anti-RALY primary antibody (1:500-1:1,000 dilution) overnight at 4°C

• Wash four times with 1× TBST (5 minutes each)

• Incubate with HRP-labeled secondary antibody (1:4,000 dilution)

• Wash four times with 1× TBST (5 minutes each)

• Develop using ECL chromogenic solution and expose

• Look for a specific band at approximately 38 kDa

Including positive controls (RALY-expressing tissues) and negative controls (knockdown samples) enhances result reliability. Western blotting has been crucial in demonstrating RALY degradation during viral infection and confirming successful knockdown/overexpression in experimental designs .

How can researchers analyze RALY association with translation complexes?

To investigate RALY's association with translation machinery:

• Polysome profiling:

  • Treat cells with cycloheximide (CHX) to stabilize ribosomes on mRNA

  • Fractionate cell extracts on 5%-50% linear sucrose density gradients

  • Monitor UV absorbance (OD254) to identify ribosomal fractions

  • Analyze fractions by Western blotting for RALY, 40S (RPS5), and 60S (RPLP0) markers

• Co-immunoprecipitation:

  • Immunoprecipitate with anti-RALY antibodies from mock or infected cells

  • Perform Western blotting for translation initiation factors (eIF2α, eIF3A, eIF3e, eIF4A, eIF4G)

  • Include appropriate controls (IgG, input samples)

These approaches have revealed that RALY associates with 40S ribosomal subunits and translation initiation factors, particularly in virus-infected cells, supporting its role in translation regulation .

How does RALY inhibit viral replication at the molecular level?

RALY exhibits antiviral activity through a specific molecular mechanism:

• RALY binds to domain 3 (D3) of the FMDV IRES through its RNA recognition motif (RRM)

• This binding does not prevent the assembly of translation initiation complexes with 40S ribosomes

• Instead, RALY specifically blocks the formation of 80S ribosome complexes on the FMDV IRES after 40S binding

• This inhibition prevents viral mRNA translation and subsequent viral protein synthesis

• RALY shows stronger binding to translation components in virus-infected cells compared to uninfected cells

Importantly, FMDV has evolved a countermeasure: its 3C protease targets RALY for degradation via the ubiquitin-proteasome pathway, neutralizing this host defense mechanism . This represents a classic example of the evolutionary arms race between host antiviral factors and viral countermeasures.

How can RALY knockdown and overexpression experiments be designed and validated?

For effective RALY manipulation experiments:

RALY knockdown:

• Transfect cells with RALY-specific siRNA (e.g., siRALY-sense 5′-GCCUUUGUCCAGUAUGCCATT-3′) and negative control siRNA

• Incubate for 36-48 hours

• Validate knockdown efficiency by Western blotting with RALY antibodies

• Infect with virus (e.g., FMDV at MOI=1)

• Collect samples at various timepoints (1, 3, 5, 7, 9 hpi)

• Analyze viral replication by qPCR, TCID50, and Western blotting

RALY overexpression:

• Transfect cells with Flag-RALY expression plasmid or empty vector

• Incubate for 24 hours

• Confirm overexpression by Western blotting

• Infect with virus

• Collect samples and analyze as above

These experiments typically show enhanced viral replication upon RALY knockdown and reduced replication with overexpression, confirming RALY's antiviral function.

What experimental controls are essential when studying RALY-RNA interactions?

When investigating RALY-RNA interactions, include these critical controls:

• Input control: Analyze a portion of pre-immunoprecipitation lysate to confirm target RNA presence

• Negative antibody control: Use isotype-matched IgG to assess non-specific binding

• No-antibody control: Process samples without antibody addition

• Non-target RNA controls: Include primers for housekeeping RNAs (e.g., RPS16, GAPDH) that shouldn't associate with RALY

• RNase treatment control: Treat parallel samples with RNase to confirm RNA-dependent interactions

• Competitive binding controls: Use known RALY-binding RNAs as competitors

The FMDV research included appropriate control amplifications of housekeeping genes (RPS16, GAPDH) and multiple viral RNA regions to establish binding specificity to the IRES element .

How can researchers study the differential association of RALY with cellular machinery during viral infection?

To examine how RALY associations change during infection:

• Comparative immunoprecipitation:

  • Perform IP with RALY antibodies from mock and virus-infected cells

  • Compare co-precipitated proteins by Western blotting or mass spectrometry

  • Analyze for changes in association with translation factors

• Subcellular fractionation:

  • Separate nuclear and cytoplasmic compartments

  • Perform Western blotting for RALY in each fraction

  • Compare distribution patterns between mock and infected states

• Sucrose gradient analysis:

  • Compare RALY distribution in polysome profiles between mock and infected cells

  • Quantify shifts in association with 40S, 60S, 80S, and polysome fractions

Such approaches have revealed that during FMDV infection, RALY shows increased association with 40S ribosomal subunits and translation initiation factors, including cleaved eIF4G, eIF3A, eIF3e, eIF4A, and eIF2α but not eIF5B .

How can RALY antibodies be used to investigate post-translational modifications during infection?

For studying RALY modifications during viral infection:

• 2D gel electrophoresis:

  • Immunoprecipitate RALY from mock and infected cells

  • Separate by isoelectric focusing followed by SDS-PAGE

  • Western blot with RALY antibodies to detect charge or size shifts

• Modification-specific detection:

  • Immunoprecipitate RALY from infected and uninfected cells

  • Probe with antibodies against specific modifications (ubiquitin, SUMO, phospho-groups)

  • Compare modification patterns between conditions

• In vitro modification assays:

  • Express recombinant RALY

  • Incubate with viral proteins (e.g., 3C protease)

  • Analyze modification status by Western blotting

These approaches would extend current understanding of how FMDV 3C protease targets RALY for degradation via the ubiquitin-proteasome pathway .

What are common issues with RALY antibodies in Western blotting and their solutions?

When troubleshooting RALY antibody Western blotting:

Weak signal problems:

• Increase primary antibody concentration (try 1:250 instead of 1:1,000)

• Extend primary antibody incubation (overnight at 4°C)

• Use more sensitive detection reagents

• Increase protein loading

• Optimize transfer conditions for the 38 kDa range

Non-specific bands:

• Increase blocking stringency (5% BSA instead of milk)

• Use more stringent washing (higher salt in TBST)

• Reduce primary antibody concentration

• Include appropriate positive control (RALY-overexpressing sample)

• Include negative control (RALY-knockdown sample)

Research with RALY antibodies has successfully detected both endogenous RALY and overexpressed Flag-RALY in various experimental conditions, demonstrating their reliability when properly optimized .

How can researchers validate the specificity of RALY antibodies in their experimental system?

To validate RALY antibody specificity:

• Genetic approaches:

  • Perform siRNA knockdown of RALY (e.g., using sequence 5′-GCCUUUGUCCAGUAUGCCATT-3′)

  • Compare antibody signal in control vs. knockdown samples by Western blotting

  • Expect significant reduction in the 38 kDa RALY band in knockdown samples

• Overexpression validation:

  • Transfect cells with Flag-RALY expression construct

  • Perform parallel detection with anti-RALY and anti-Flag antibodies

  • Confirm co-localization of signals

• Cross-species reactivity testing:

  • Test antibody against samples from different species (human, mouse, rat)

  • Confirm expected molecular weight bands in each species

  • Compare observed patterns with predicted cross-reactivity

• Immunoprecipitation-Western validation:

  • Immunoprecipitate with RALY antibody

  • Perform Western blotting on precipitate with a different RALY antibody

  • Confirm specific enrichment of RALY protein

These validation approaches ensure experimental results accurately reflect RALY biology rather than non-specific antibody interactions.

What primers and protocols are recommended for quantifying RALY mRNA levels?

For accurate quantification of RALY mRNA levels:

Protocol:

• Extract total RNA using TRIzol Reagent

• Perform reverse transcription to generate cDNA

• Set up qPCR reactions with SYBR Green or probe-based detection

• Include no-template and RT-minus controls

• Use the comparative Ct method (2^-ΔΔCt) for relative quantification

• Normalize to multiple reference genes (e.g., GAPDH and RPS16)

This approach enables accurate quantification of RALY expression changes during experimental manipulations or viral infection.

How can the TCID50 assay be used to correlate RALY expression with viral replication?

The TCID50 (Tissue Culture Infectious Dose 50%) assay protocol for correlating RALY expression with viral replication:

• Transfect cells with RALY siRNA or overexpression plasmid

• After appropriate incubation (36-48h for knockdown, 24h for overexpression), infect with virus (MOI=1)

• Collect cells and supernatant at various timepoints post-infection

• Freeze-thaw samples three times to release virions

• Prepare serial dilutions of each sample

• Add dilutions to 96-well plates (8 wells per dilution, 100 μL per well)

• Add 100 μL of BHK-21 cell suspension (1.5 × 10^6 cells/mL) to each well

• Incubate at 37°C, 5% CO2 for approximately 70 hours

• Count wells showing cytopathic effects

• Calculate TCID50 using the Reed-Muench method

This assay has demonstrated that RALY knockdown significantly increases viral titers while overexpression decreases them, confirming RALY's antiviral function in a quantitative manner .

How might RALY antibodies be used to investigate broader roles in additional virus families?

Future research applications of RALY antibodies could include:

• Comparative virus studies:

  • Apply established RIP, IP, and Western blotting protocols to diverse virus families

  • Compare RALY binding to IRES elements from different viruses

  • Evaluate RALY degradation by various viral proteases

• Mechanism dissection:

  • Use RALY mutants and deletion constructs to map functional domains

  • Identify specific amino acids required for antiviral activity

  • Investigate RALY post-translational modifications across virus infections

• Therapeutic development:

  • Screen for compounds that stabilize RALY against viral degradation

  • Develop peptide mimetics of RALY's RNA-binding domain

  • Test gene therapy approaches to deliver degradation-resistant RALY

• In vivo infection models:

  • Use RALY antibodies for tissue immunohistochemistry in infected animals

  • Compare RALY levels and distribution across tissues during infection

  • Correlate with viral load and pathology

These approaches would expand our understanding of RALY's potentially broad antiviral activities beyond FMDV .

What is the relationship between RALY's normal cellular functions and its antiviral activity?

Understanding the dual role of RALY requires:

• Comparative RIP-seq analysis:

  • Immunoprecipitate RALY from mock and infected cells

  • Perform RNA sequencing of bound transcripts

  • Compare cellular vs. viral RNA binding profiles

• Cellular impact assessment:

  • Monitor changes in cellular RNA processing during RALY recruitment to viral RNAs

  • Identify cellular processes affected by RALY sequestration

  • Determine whether viral targeting of RALY serves purposes beyond neutralizing antiviral activity

• Evolutionary analysis:

  • Compare RALY sequences across species with differential viral susceptibility

  • Identify positively selected residues that may indicate virus-host coevolution

  • Test chimeric RALY proteins for species-specific antiviral activity

This research would help determine whether RALY's antiviral function evolved specifically as a host defense mechanism or represents viral exploitation of RALY's normal cellular functions in RNA metabolism and translation regulation .